Journal of Business Studies Quarterly 2013, Volume 4, Number 3 ISSN 2152-1034 Intellectual Property Rights (IPRs) and Pharmaceutical Manufacturing Organizations' Business Performance. Dr. Abdel-Aziz Ahmad Sharabati, Middle East University, Jordan Prof. Dr. Abdul-Naser Ibrahim Nour, Middle East University, Jordan Abstract The purpose of the study is to investigate the influence of Intellectual Property Rights (IPRs) on Jordanian Pharmaceutical Manufacturing (JPM) Organizations’ Business Performance (BP). Practical data were used in the empirical analysis collected from 126 managers out of 250 managers of the mentioned organizations, by means of a questionnaire. Statistical techniques such as descriptive statistics, t-test, ANOVA test, correlation, multiple regressions, and stepwise regressions were employed. To confirm the suitability of data collection instrument, a Kolmogorov-Smirnov (K-S) test, Cronbach’s Alpha and factor analysis were used. The results of the study indicated a positive significant relationship between IPRs and Pharmaceutical Organizations’ business performance. The use of a single industry study design limits its generalisability to other industries. The research results might help both academics and practitioners to be more ready to understand the components of IPRs and provide insight into developing and increasing them within their organizations. IPRs are an important source of organizations’ wealth and therefore it should be taken into serious consideration when formulating the JPM Organizations’ strategy. This study extends prior research’s viewpoint about the linear relationship between IPRs and organizations’ BP with empirical evidence. Key words: Intellectual Property Rights (IPRs), Innovation and Creation (I&C), Research and Development (R&D), Intellectual Assets (IA), Jordanian Pharmaceutical Manufacturing (JPM) Organizations, Business Performance (BP). 1. Introduction: The process of globalization and the emergence of a rules-based multilateral trading system pose significant challenges to local pharmaceutical industries in developing countries (Kılıc, 2011). The pharmaceutical industry is currently undergoing significant change, driven by factors such as declining research and development (R&D), vigorous competition from generics industry, the emergence of new markets in middle-income countries, and social pressures (Wellcome Trust, 2011). The term intellectual property rights (IPRs) refers to those legal rules, norms and regulations that prevent the unauthorized use of intellectual products (Merrill and Elliott, 2004). IPRs essentially consist of two domains: one deal with industrial products, which includes patents,